Endothelial Function Guided Therapy in Patients With Non-obstructive Coronary Artery Disease

Endothelial Function Guided Therapy in Patients With Non-obstructive Coronary Artery Disease (EndoFIND Study)

The purpose of this study is to systematically evaluate the clinical application value of vascular endothelial function examination in patients with non-obstructive coronary artery disease.

The study will be carried out in two stages. Phase I is mainly intended to evaluate the effects of vascular EFT on the prescription of doctors and the application rate of mid and long-term secondary prevention medication in patients. If the results are positive, the sample size and observation time will be further expanded in Phase II to evaluate its impact on the cardiovascular events of patients, as well as its cost-effectiveness.

Inclusion Criteria:

• 1. Age: 18 years or older;
• 2. Patients with NOCAD defined by CT or CAG results of less than 50% occlusion;
• 3. Having signed their written informed consent.

Exclusion Criteria:

• 1. Left ventricular ejection fraction ≤ 50%;
• 2. Serious endocrine diseases (severe hyperthyroidism, hypothyroidism);
• 3. Severe liver diseases (jaundice hepatitis, liver cirrhosis, liver failure);
• 4. Severe nephropathy (uremia, renal failure);
• 5. Severe inflammatory diseases (severe infection, lupus erythematosus, etc.);
• 6. Malignant tumor;
• 7. Mental disorders or cognitive disorders;
• 8. Participating in other interventional clinical trials;
• 9. There are any other factors that the treating doctors think are not suitable for inclusion or completion of this study.